Publication
Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine.
Authors not recorded
Head Neck Oncol2010PMID 20504363PMC2889991stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerMalignant Salivary Gland Neoplasmcivic_curation1.00
- drugCapecitabinecivic_curation1.00
- drugTrastuzumabcivic_curation1.00
- drugZoledronic Acidcivic_curation1.00
- geneERBB2civic_curation1.00
- variantERBB2 Overexpressioncivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 20504363
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ERBB2 Overexpression1 | ||||||||
| Capecitabine + Trastuzumab + Zoledronic AcidCombination | Malignant Salivary Gland NeoplasmALIAS | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID6171Case report of a a 58 year old man with multiple bone metastases after local therapy of a carcinoma ex pleomorphic adenoma one year earlier. The original tumor tested strongly positive for HER2/neu by… (full text at CIViC) PMID 20504363 · Sharon et al., 2010 · Open in CIViC | civic |